Dr. Tabernero on Molecular Characterization in GI Cancer

Josep Tabernero, MD, PhD
Published: Friday, Jul 12, 2013

Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Defining unique subtypes within broad tumor classes will help researchers discover key underlying molecular drivers, Tabernero states. Once discovered, these molecular classifications will aid the development of focused targeted agents for patients with advanced malignancies.

Initially, Tabernero believes, the application of these unique molecular characterizations, gene profiles, and expressed proteins will apply mostly to advanced disease. However, they will be translated into earlier stages through the introduction of new treatment options. These targeted treatment approaches, Tabernero states, will result in better treatment outcomes than conventional therapies.

Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, believes that in order to treat patients with gastrointestinal cancers more effectively, researchers must focus on the molecular classification of particular subpopulations.

Defining unique subtypes within broad tumor classes will help researchers discover key underlying molecular drivers, Tabernero states. Once discovered, these molecular classifications will aid the development of focused targeted agents for patients with advanced malignancies.

Initially, Tabernero believes, the application of these unique molecular characterizations, gene profiles, and expressed proteins will apply mostly to advanced disease. However, they will be translated into earlier stages through the introduction of new treatment options. These targeted treatment approaches, Tabernero states, will result in better treatment outcomes than conventional therapies.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x